These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
215 related articles for article (PubMed ID: 26417683)
21. Phorbol ester-induced shedding of the prostate cancer marker transmembrane protein with epidermal growth factor and two follistatin motifs 2 is mediated by the disintegrin and metalloproteinase-17. Ali N; Knaüper V J Biol Chem; 2007 Dec; 282(52):37378-88. PubMed ID: 17942404 [TBL] [Abstract][Full Text] [Related]
22. Loss of Nkx3.1 expression in the transgenic adenocarcinoma of mouse prostate model. Bethel CR; Bieberich CJ Prostate; 2007 Dec; 67(16):1740-50. PubMed ID: 17929276 [TBL] [Abstract][Full Text] [Related]
23. Systemic Ablation of Pulliam TL; Awad D; Han JJ; Murray MM; Ackroyd JJ; Goli P; Oakhill JS; Scott JW; Ittmann MM; Frigo DE Cells; 2022 Jun; 11(12):. PubMed ID: 35741020 [TBL] [Abstract][Full Text] [Related]
24. Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model. Foster BA; Gingrich JR; Kwon ED; Madias C; Greenberg NM Cancer Res; 1997 Aug; 57(16):3325-30. PubMed ID: 9269988 [TBL] [Abstract][Full Text] [Related]
25. Preclinical validation of anti-TMEFF2-auristatin E-conjugated antibodies in the treatment of prostate cancer. Afar DE; Bhaskar V; Ibsen E; Breinberg D; Henshall SM; Kench JG; Drobnjak M; Powers R; Wong M; Evangelista F; O'Hara C; Powers D; DuBridge RB; Caras I; Winter R; Anderson T; Solvason N; Stricker PD; Cordon-Cardo C; Scher HI; Grygiel JJ; Sutherland RL; Murray R; Ramakrishnan V; Law DA Mol Cancer Ther; 2004 Aug; 3(8):921-32. PubMed ID: 15299075 [TBL] [Abstract][Full Text] [Related]
26. Lobe-specific proteome changes in the dorsal-lateral and ventral prostate of TRAMP mice versus wild-type mice. Zhang J; Wang L; Zhang Y; Li L; Higgins L; Lü J Proteomics; 2011 Jun; 11(12):2542-9. PubMed ID: 21598396 [TBL] [Abstract][Full Text] [Related]
27. Nintedanib antiangiogenic inhibitor effectiveness in delaying adenocarcinoma progression in Transgenic Adenocarcinoma of the Mouse Prostate (TRAMP). da Silva RF; Nogueira-Pangrazi E; Kido LA; Montico F; Arana S; Kumar D; Raina K; Agarwal R; Cagnon VHA J Biomed Sci; 2017 May; 24(1):31. PubMed ID: 28499383 [TBL] [Abstract][Full Text] [Related]
28. NFATc1 promotes prostate tumorigenesis and overcomes PTEN loss-induced senescence. Manda KR; Tripathi P; Hsi AC; Ning J; Ruzinova MB; Liapis H; Bailey M; Zhang H; Maher CA; Humphrey PA; Andriole GL; Ding L; You Z; Chen F Oncogene; 2016 Jun; 35(25):3282-92. PubMed ID: 26477312 [TBL] [Abstract][Full Text] [Related]
29. Lack of high-dose radiation mediated prostate cancer promotion and low-dose radiation adaptive response in the TRAMP mouse model. Lawrence MD; Ormsby RJ; Blyth BJ; Bezak E; England G; Newman MR; Tilley WD; Sykes PJ Radiat Res; 2013 Oct; 180(4):376-88. PubMed ID: 23971516 [TBL] [Abstract][Full Text] [Related]
30. The G gamma / T-15 transgenic mouse model of androgen-independent prostate cancer: target cells of carcinogenesis and the effect of the vitamin D analogue EB 1089. Perez-Stable CM; Schwartz GG; Farinas A; Finegold M; Binderup L; Howard GA; Roos BA Cancer Epidemiol Biomarkers Prev; 2002 Jun; 11(6):555-63. PubMed ID: 12050097 [TBL] [Abstract][Full Text] [Related]
32. Gene expression profile of mouse prostate tumors reveals dysregulations in major biological processes and identifies potential murine targets for preclinical development of human prostate cancer therapy. Haram KM; Peltier HJ; Lu B; Bhasin M; Otu HH; Choy B; Regan M; Libermann TA; Latham GJ; Sanda MG; Arredouani MS Prostate; 2008 Oct; 68(14):1517-30. PubMed ID: 18668517 [TBL] [Abstract][Full Text] [Related]
34. The resistance to the tumor suppressive effects of COX inhibitors and COX-2 gene disruption in TRAMP mice is associated with the loss of COX expression in prostate tissue. Wang X; Colby JK; Yang P; Fischer SM; Newman RA; Klein RD Carcinogenesis; 2008 Jan; 29(1):120-8. PubMed ID: 17942462 [TBL] [Abstract][Full Text] [Related]
35. Repression of the TMEFF2 promoter by c-Myc. Gery S; Koeffler HP J Mol Biol; 2003 May; 328(5):977-83. PubMed ID: 12729735 [TBL] [Abstract][Full Text] [Related]
36. Siah2-dependent concerted activity of HIF and FoxA2 regulates formation of neuroendocrine phenotype and neuroendocrine prostate tumors. Qi J; Nakayama K; Cardiff RD; Borowsky AD; Kaul K; Williams R; Krajewski S; Mercola D; Carpenter PM; Bowtell D; Ronai ZA Cancer Cell; 2010 Jul; 18(1):23-38. PubMed ID: 20609350 [TBL] [Abstract][Full Text] [Related]
37. Bidirectional regulation between TMEFF2 and STAT3 may contribute to Helicobacter pylori-associated gastric carcinogenesis. Sun TT; Tang JY; Du W; Zhao HJ; Zhao G; Yang SL; Chen HY; Hong J; Fang JY Int J Cancer; 2015 Mar; 136(5):1053-64. PubMed ID: 24996057 [TBL] [Abstract][Full Text] [Related]
38. High animal fat intake enhances prostate cancer progression and reduces glutathione peroxidase 3 expression in early stages of TRAMP mice. Chang SN; Han J; Abdelkader TS; Kim TH; Lee JM; Song J; Kim KS; Park JH; Park JH Prostate; 2014 Sep; 74(13):1266-77. PubMed ID: 25053105 [TBL] [Abstract][Full Text] [Related]
39. Elevated expression of 12/15-lipoxygenase and cyclooxygenase-2 in a transgenic mouse model of prostate carcinoma. Shappell SB; Olson SJ; Hannah SE; Manning S; Roberts RL; Masumori N; Jisaka M; Boeglin WE; Vader V; Dave DS; Shook MF; Thomas TZ; Funk CD; Brash AR; Matusik RJ Cancer Res; 2003 May; 63(9):2256-67. PubMed ID: 12727848 [TBL] [Abstract][Full Text] [Related]
40. Genetic ablation of PKC epsilon inhibits prostate cancer development and metastasis in transgenic mouse model of prostate adenocarcinoma. Hafeez BB; Zhong W; Weichert J; Dreckschmidt NE; Jamal MS; Verma AK Cancer Res; 2011 Mar; 71(6):2318-27. PubMed ID: 21406403 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]